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Stem cell therapies have the potential to revolutionize the way we practice medicine. However, in the current
climate several barriers and false assumptions stand in the way of achieving that goal.The first two precepts of the modified
Hippocratic Oath, which all M.D. gradu-
ates pledge are, in paraphrase: first, do
no harm; and second, the primary obliga-
tion of a physician is to the health of the
patient (to which I add ‘‘and future
patients’’), and a physician will not let
issues of race, creed, religion, politics, or
personal ethics to stand between the
patient’s health and his/her actions. The
stem cell field, probably more than any I
know of in medical science, is plagued
by failures to act responsibly on both
precepts.
While I am usually an optimist, I must
admit that there is a possibility that
we will continue to be in the Dark Ages
of medicine for quite some time. I fear
that therapies using purified tissue and
organ-specific stem cells—the only self-
renewing cells in a tissue or that can
regenerate that tissue or organ for life—
will remain elusive. Before I go further,
just think about that statement: regen-
erate that tissue or organ for life. No
pharmaceutical, no biotech-developed
protein, and no other transplanted cells
can do that. If we can deliver purified
stem cells safely and effectively as a
one-time therapy, we can change medi-
cine, especially for diseases that drugs
and proteins can’t touch. Moreover, if
we manage the costs and charges care-
fully, this form of therapy could lower
overall health care costs dramatically.
This vision is based on solid scientific
evidence that stem cells regularly main-
tain, and, if necessary, regenerate tissues
in a homeostatically controlled process.
So it’s worth the extra effort to find
a way to make it happen.
Doing Harm
One of the barriers to practicing stem-
cell-based regenerative medicine is theexistence of fraudulent clinics and indi-
viduals who claim unproven therapies
without underlying scientific backing. In
many cases, they use cells that have
never been tested experimentally for their
‘‘stemness,’’ have not been through IRB-
approved protocols that demand experi-
mental evidence to justify the human
experiment, and lack both independent
medical monitoring of patient safety and
oversight by a state or country regulatory
system such as the FDA. It is critical that,
as the community that speaks for stem
cell biology and stem cell medicine, we
find ways to warn patients and caregivers
effectively about these concerns (Taylor
et al., 2010).
There is also a fine line between these
clearly fraudulent practices and question-
able ones that use the stem cell label, but
are not in fact stem cell therapies. For
example, cultures of adherent cells from
bone marrow, cord blood, or adipose
tissue are regularly claimed to be mesen-
chymal stem cells (MSCs), but in such
cultures true stem cells that both self-
renew and differentiate to mesenchymal
fates such as bone, cartilage, fibroblasts,
and adipocytes are rare. Mesenchymal
stromal cells, as apopulation,maycontain
cells that produce immunomodulatory
and/or angiogenic factors, but are not
sufficiently purified or defined to be a
characterized entity for research or clin-
ical transplantation. Finding markers that
help define these populations was an
important step (Dominici et al., 2006),
but until there is a better understanding
of howmany of these cells can self-renew
and give robust regeneration, I do not
think they should be called stem cells.
There are alsomany claims that mesen-
chymal and/or hematopoietic cells can
transdifferentiate without gene modifi-
cation to make brain, liver, heart, skeletalCell Stem Cellmuscle, or other tissues. However, these
claims lack rigorous scientific support
(Wagers and Weissman, 2004). Highly
visible athletes and politicians are among
the many patients who have received
such ‘‘treatments.’’ Recently, the Texas
Medical Board approved a policy that
allows licensed physicians to transplant
investigational agents, including MSCs,
with IRB approval but without a require-
ment for FDA approval of safety and
efficacy. In my view, this lack of a require-
ment for FDA oversight and approval for
both safety and efficacy is a giant step
backward.
Another example of questionable stem
cell practices comes from some commer-
cial private cord blood banks. Cord
blood does contain both HSCs and
mesenchymal progenitors. The number
of HSCs in each cord is sufficient to give
rapid generation of blood only in infants
and very small children, and above the
age of 7, several HLA-matched cords
are needed. The development of public
cord blood banks is an important, life-
saving advance for patients needing
hematopoietic cell transplants but lacking
matched donors. However, this activity is
very different from the private cord blood
banks that charge significant amounts to
initiate freezing of cord blood cells and
then maintain them in case the child
from whom the cord is obtained needs
therapy. These companies often list
a broad range of diseases that now or
someday will be treated with stem cells
without warning the patients or caregivers
that the evidence that cord blood cells will
be useful for treating such diseases is still
very limited, and in any case the stored
cord blood has the same genetic back-
ground as the child from whom the cord
was obtained. The overall cause of legiti-
mate stem cell therapy would be greatly10, June 14, 2012 ª2012 Elsevier Inc. 663
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sight of these and other organizations
making unsupported claims about the
potential of stem-cell-based treatments.
The Therapeutic Entity Is the Stem
Cell Itself
Very few ‘‘adult’’ stem cells have been
prospectively isolated, and only prospec-
tively isolated blood-forming stem cells
(HSCs) and brain-forming stem cells
(NSCs) have been transplanted in clinical
trials (Baum et al., 1992; Uchida et al.,
2000). Grafts of other tissues, such as
skin and bone marrow, depend on the
stem cells in that tissue, but prospectively
isolated stem cells are usually not used.
Instead of using cells as the therapy, as
a general rule, large drug companies are
approaching the use of disease specific
iPSCs or adult stem cells as tools for
chemical or protein screens to find
compounds that can be taken as conven-
tional drugs to treat diseases. Some of
these efforts are focused on differentiated
cells derived from stem cells, but others
aim to address diseases where altered
or insufficient numbers of stem cells
are central to the disease. The principal
property of stem cells that makes them
special is their ability to self-renew and
reconstitute cell populations. Inducing
self-renewal in vivo could be difficult to
achieve because many factors affect
stem cell regulation. It seems unlikely
that single molecules will be able to acti-
vate all of the necessary pathway genes
appropriately to expand a stem cell pool
and allow robust and physiologically
significant regeneration. Thus, I think this
approach is likely to fall short as a method
to replace tissue stem cells in vivo, and
efforts will need to focus more on trans-
planting the cells themselves. However,
stem-cell-regulating agents derived from
screening could still be used as adjuvants
for transplanted stem cells.
At a broader level, HSCs themselves
form a foundation on which the rest of
the regenerative medicine field could be
built. When engrafted, purified HSCs can
replace the hematopoietic system. By
doing so, they also render the host
permanently tolerant to other organs,
tissues, or tissue stem cells from the
same donor without further immune
suppression (Weissman and Shizuru,
2008). In the future, the isolation of
HSCs and other tissue stem cells (e.g.,664 Cell Stem Cell 10, June 14, 2012 ª2012NSCs) from the same donor could come
from pluripotent stem cell lines, and
not living or recently deceased donors.
Pluripotent ESC or iPSC line production
of HSCs is still not practical, and working
out the pathways to achieve that objective
remains a critical roadblock to expanding
the field of regenerative medicine.
In Vivo Veritas
The experiments that validated human,
purified HSCs for hematopoietic trans-
plants and human brain-stem-cell-
derived neurospheres for neural disease
transplants used immune-deficient mice
that were crucial in testing the potential
therapeutic effectiveness of these cells
in vivo (Weissman, 2002). Although the
derivation of patient- and disease-
specific iPSCs can allow experiments in
a petri dish, the disease pathogenesis
caused by inherited mutations would
be more completely understood if the
cells could mature in a more physiological
setting. One way to study them would
be to develop blastocyst chimeras that
are implanted and allowed to develop.
Mouse ESCs and iPSCs can already be
studied using this type of approach.
Currently, human ESCs/iPSCs do not
form chimeras if placed in mouse blasto-
cysts and implanted. However, human
pluripotent stem cell lines are mainly
at the epiblast stage, and not the preim-
plantation blastocyst, and even mouse
epiblast cells cannot form long-term blas-
tocyst chimeras. If the substantial prac-
tical and ethical issues could be over-
come, blastocyst chimeras with human
iPSCs might provide insights into the
cellular and molecular mechanisms of
human disease pathogenesis, and the
gene expression programs that allow
embryonic tissue stem cells to mature.
An Unexpected but Potent Barrier:
Business Development
Growing up in America, it is obvious to all
of us that the transition from discovery to
therapy almost always involves for-profit
entities. Ingenuity and innovation are hall-
marks of our society, and so it is natural
that the prospective identification and
isolation of adult or tissue stem cells leads
to business enterprises. I myself have co-
founded several companies that have
done discovery, preclinical proof of prin-
ciple, and even phase I/II clinical trials in
the stem cell field. Each has succeededElsevier Inc.in the discovery and preclinical phases,
but found that the results of the clinical
trials can take a back seat to business
decisions. For example, SyStemix Inc.
was a 1988 Palo Alto startup that identi-
fied a method to prospectively isolate
and transplant clinically relevant numbers
of human HSCs. The company entered
a relationship with Sandoz, Inc. to explore
autologous and allogeneic HSC thera-
pies. Purification of mobilized peripheral
blood HSCs resulted in depletion of
various metastatic cancer cells by
115,000- to 245,000-fold (Prohaska and
Weissman, 2009), and thus could be
used to reconstitute the hematopoietic
system after therapy with a reduced risk
of reintroducing tumor cells. This finding
led to clinical trials.
Twenty-two patients with metastatic
breast cancer underwent transplantation
of previously mobilized HSCs after very-
high-dose chemotherapy. Although the
trials were small, two hypotheses were
tested: (1) can one improve the outcome
of patients with chemoresistant metas-
tases? And (2) can one improve the
outcomes of relapse patients with both
metastases and chemoresponsive can-
cers? The therapy did not help the patients
with chemoresistant breast cancers.
However, at 3 years the chemoresponsive
cohort who received cancer-depleted
HSCs appeared to be doing better than
patients with standard mobilized periph-
eral blood transplants. At that point, San-
doz merged with CIBA to form Novartis,
and within a few years the stem cell
program was cancelled. Last year Antonia
Mu¨ller and Judy Shizuru published the
follow-up of the patients 13–15 years later
(Mu¨ller et al., 2012). One-third of the
patients who received purified HSCs were
still alive, contrasting with the 7% overall
survival of 78 contemporaneous Stanford
patients with stage IV breast cancer who
received standard, unpurified, mobilized
peripheral blood transplant therapy. Of
the five long-term surviving patients who
had received purified HSCs, four had no
recurrence of their breast cancers.
Attempts to reinitiate the program in
another startup, helped by Novartis
management, were halted when consul-
tant oncologists advised investors that
stem cell therapies in breast cancer
had failed, citing a study indicating
that ‘‘stem cell’’ rescue of high-dose
chemotherapy patients with metastatic
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therapy alone, that is, only 6% disease-
free survival at 2 years (Stadtmauer et al.,
2000). However, Stadtmauer et al. trans-
planted unfractionated mobilized blood,
not purified HSCs, and no amount of
evidence about the difference could
counter the words ‘‘stem cell’’ in the
title of the NEJM article. This particular
problem could have been avoided
by more rigorous editorial standards
regarding the use of the term ‘‘stem
cell,’’ and I would argue that improved
accuracy in this respect would benefit
many areas of the field.
How can we resolve this conflict of
goals, that of a company to make a profit,
and that of the biomedical researcher to
advance medical science for the benefit
of patients? The largest and best funding
experiment I have seen so far comes
from the California Institute of Regenera-
tive Medicine. CIRM’s charter allows it to
fund promising stem-cell-based discov-
eries to and through phase I trials, taking
out the risk that leaves our field bereft of
suitable funds and in the ‘‘valley of death.’’
However, to overcome the types of prob-
lems that the SyStemix trial encountered,
this funding would need to be taken
beyond initial trials to a point at whichthe evidence for clinical efficacy was
irrefutable.In Closing....
So, whom have I failed to annoy here? In
one way or another, I have called out
almost all of the different stakeholder
groups involved in developing stem cell
therapies. I wish I had a better story to
tell, but I am convinced that we need to
identify and reveal those who directly or
indirectly do harm with phony medicines,
and those who generate barriers to
finding and transplanting adult tissue/
organ stem cells for financial, religious,
political, or other reasons. Unless we
do, it will be difficult to usher in the
era of stem cell regenerative medicine.
Remember, right now our patients,
friends, and families are contracting
diseases that have a very short window
of opportunity in which regenerative ther-
apies can save them, and each delay
removes a cohort of them from possible
cures. We should not fail them.REFERENCES
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